Anders Tveita
YOU?
Author Swipe
View article: Antibody-secreting cell differentiation and fitness is dependent on sialophorin CD43-mediated regulation of the unfolded protein response 3498
Antibody-secreting cell differentiation and fitness is dependent on sialophorin CD43-mediated regulation of the unfolded protein response 3498 Open
Description We identified sialophorin CD43 as a regulator of BCR signaling thresholds. Here, we investigated the role of CD43 in T-cell mediated antibody-secreting cell (ASC) differentiation. CD43 Ab-targeting thwarted BCR signals and prol…
View article: High viral loads combined with inflammatory markers predict disease severity in hospitalized COVID‐19 patients: Results from the NOR‐Solidarity trial
High viral loads combined with inflammatory markers predict disease severity in hospitalized COVID‐19 patients: Results from the NOR‐Solidarity trial Open
Objectives To investigate temporal changes in the association between SARS‐CoV2 viral load (VL) and markers of inflammation during hospitalization, as well as the ability of these markers alone or in combination to predict severe outcomes.…
View article: Extracellular matrix remodelling pathway in peripheral blood mononuclear cells from severe COVID-19 patients: an explorative study
Extracellular matrix remodelling pathway in peripheral blood mononuclear cells from severe COVID-19 patients: an explorative study Open
There is a reciprocal relationship between extracellular matrix (ECM) remodelling and inflammation that could be operating in the progression of severe COVID-19. To explore the immune-driven ECM remodelling in COVID-19, we in this explorat…
View article: Neurosarcocystosis in Patient with HIV-Induced Immunodeficiency
Neurosarcocystosis in Patient with HIV-Induced Immunodeficiency Open
Sarcocystis is a genus of protozoan parasites that can infect various vertebrates. In humans, Sarcocystis infection usually is asymptomatic but might manifest as a mild gastroenteritis or extraintestinal myositis. We report a case of human…
View article: Chimeric antigen receptor T cells targeting the GM3(Neu5Gc) ganglioside
Chimeric antigen receptor T cells targeting the GM3(Neu5Gc) ganglioside Open
Chimeric antigen receptor (CAR) T cell technology has ushered in a new era of immunotherapy, enabling the targeting of a broad range of surface antigens, surpassing the limitations of traditional T cell epitopes. Despite the wide range of …
View article: Coagulopathy and adverse outcomes in hospitalized patients with COVID-19: results from the NOR-Solidarity trial
Coagulopathy and adverse outcomes in hospitalized patients with COVID-19: results from the NOR-Solidarity trial Open
TFPI and tPA are associated with severe disease in hospitalized patients with COVID-19. For TFPI, high levels measured during the first 10 days of hospitalization were also associated with persistent pulmonary pathology even 3 months after…
View article: Molecular genetic testing and measurement of levels of GPIHBP1 autoantibodies in patients with severe hypertriglyceridemia: The importance of identifying the underlying cause of hypertriglyceridemia
Molecular genetic testing and measurement of levels of GPIHBP1 autoantibodies in patients with severe hypertriglyceridemia: The importance of identifying the underlying cause of hypertriglyceridemia Open
Only 0.9% of the patients had monogenic hypertriglyceridemia, and only 0.8% had GPIHBP1 autoantibody syndrome. The latter figure is most likely an underestimate because serum samples were obtained approximately nine years after hypertrigly…
View article: Circulating markers of extracellular matrix remodelling in severe COVID‐19 patients
Circulating markers of extracellular matrix remodelling in severe COVID‐19 patients Open
Background Abnormal remodelling of the extracellular matrix (ECM) has generally been linked to pulmonary inflammation and fibrosis and may also play a role in the pathogenesis of severe COVID‐19. To further elucidate the role of ECM remode…
View article: COVID-19 patients treated with convalescent plasma
COVID-19 patients treated with convalescent plasma Open
Convalescent plasma was well tolerated by patients with COVID-19. Immunocompromised patients may have benefitted from the treatment, with lower mortality than for those assumed to be immunocompetent.
View article: A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine
A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine Open
The microenvironment of chronic lymphocytic leukemia (CLL) cells in lymph nodes, spleen, and bone marrow provides survival, proliferation, and drug resistance signals. Therapies need to be effective in these compartments, and pre-clinical …
View article: Supplementary figure S3 from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs
Supplementary figure S3 from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs Open
In vitro toxicity of Trp-specific T cells against wild type and MHC II-deficient B16 melanoma variants. Results of adoptive T cell therapy experiments in mice challenged with wild type B16 tumor cells.
View article: Supplementary Figure 2 and 3 from Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity
Supplementary Figure 2 and 3 from Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity Open
Supplementary Figure S2. OX40L, CD80 and CD86 mRNA-CART treatment induce long lasting protection against re-challenge with the same tumor cell line. Supplementary Figure S3. OX40L, CD80 and CD86 mRNA-CART treatment do not result in long te…
View article: Supplementary figure S2 from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs
Supplementary figure S2 from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs Open
T-cell stimulatory ability and cytokine profile of cells isolated from lymph nodes of mice challenged with various A20 lymphoma variants. Confirmatory data showing tumor-specific T cell infiltration in tumor and draining lymph nodes of ado…
View article: Data from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs
Data from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs Open
Tumor-specific CD4+ T cells have been shown to mediate efficient antitumor immune responses against cancer. Such responses can occur through direct binding to MHC class II (MHC II)–expressing tumor cells, or indirectly via activation of pr…
View article: Data from Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity
Data from Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity Open
Localized expression of effector molecules can initiate antitumor responses through engagement of specific receptors on target cells in the tumor microenvironment. These locally induced responses may also have a systemic effect, clearing a…
View article: Supplementary Figure S1 from Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity
Supplementary Figure S1 from Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity Open
OX40L, CD80 and CD86 mRNA-CART treatment increased the expression of CD80, CD86 and OX40L protein on tumor infiltrating cells
View article: Data from Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity
Data from Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity Open
Localized expression of effector molecules can initiate antitumor responses through engagement of specific receptors on target cells in the tumor microenvironment. These locally induced responses may also have a systemic effect, clearing a…
View article: Supplementary figure S3 from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs
Supplementary figure S3 from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs Open
In vitro toxicity of Trp-specific T cells against wild type and MHC II-deficient B16 melanoma variants. Results of adoptive T cell therapy experiments in mice challenged with wild type B16 tumor cells.
View article: Supplementary Figure S1 from Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity
Supplementary Figure S1 from Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity Open
OX40L, CD80 and CD86 mRNA-CART treatment increased the expression of CD80, CD86 and OX40L protein on tumor infiltrating cells
View article: Data from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs
Data from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs Open
Tumor-specific CD4+ T cells have been shown to mediate efficient antitumor immune responses against cancer. Such responses can occur through direct binding to MHC class II (MHC II)–expressing tumor cells, or indirectly via activation of pr…
View article: Supplementary Figure 2 and 3 from Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity
Supplementary Figure 2 and 3 from Local Delivery of <i>Ox40l</i>, <i>Cd80</i>, and <i>Cd86</i> mRNA Kindles Global Anticancer Immunity Open
Supplementary Figure S2. OX40L, CD80 and CD86 mRNA-CART treatment induce long lasting protection against re-challenge with the same tumor cell line. Supplementary Figure S3. OX40L, CD80 and CD86 mRNA-CART treatment do not result in long te…
View article: Supplementary figure S4 from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs
Supplementary figure S4 from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs Open
Flow cytometry characterization of tumor-infiltrating CD11b+ cells, and mean MHC II expression levels on CD11b+ cells isolated from tumors following challenge with the A20 lymphoma variants F9 or F59.
View article: Supplementary figure S1 from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs
Supplementary figure S1 from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs Open
Flow cytometry characterization of costimulatory ligands of A20 lymphoma cell variants
View article: Supplementary figure S1 from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs
Supplementary figure S1 from CD4<sup>+</sup> T-cell–Mediated Rejection of MHC Class II–Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs Open
Flow cytometry characterization of costimulatory ligands of A20 lymphoma cell variants